This report provides a concise, practical guide for life sciences companies evaluating manufacturing and R&D locations in the MENA region and Türkiye.
Against a backdrop of young, increasingly skilled populations and ambitious national healthcare and industrial strategies, the region is emerging as a compelling destination for Foreign and Domestic Direct Investments into pharmaceutical, biotech, and medtech R&D and manufacturing operations. The report also provides details on the potential for running clinical trials in the countries covered in this report.
We outline the key site selection criteria, which include regulatory maturity, talent availability, ecosystem depth, incentives, and geopolitical stability. This highlights how different countries are positioning themselves through localization programs, digital health initiatives, and targeted FDI policies. The report is designed to support decision-makers in comparing options, understanding risks and opportunities, and shaping a robust localization and growth strategy in MENA and Türkiye.
